行情

EYEG

EYEG

Eyegate制药
NASDAQ

实时行情|Nasdaq Last Sale

4.490
-0.010
-0.22%
盘后: 4.490 0 0.00% 16:36 03/27 EDT
开盘
4.490
昨收
4.500
最高
4.490
最低
4.034
成交量
3.40万
成交额
--
52周最高
12.89
52周最低
2.250
市值
2,077.41万
市盈率(TTM)
-1.9524
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EYEG价格均价为90.00,最高价位90.00,最低价为90.00。

EPS

EYEG 新闻

更多
  • 华尔街投行杰富瑞集团CFO死于新冠病毒并发症
  • 新浪美股 · 18分钟前
  • 姆努钦:小企业贷款计划将于本周启动
  • 新浪美股 · 54分钟前
  • 李显龙:抗疫斗争正在升级 旅游、航空业几乎已死
  • 新浪美股 · 1小时前
  • 因“沟通有误”错过欧盟集中采购 英国面临呼吸机严重短缺
  • 新浪财经 · 3小时前

所属板块

制药
-0.41%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

EYEG 简况

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
展开

微牛提供Eyegate Pharmaceuticals Inc(NASDAQ-EYEG)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EYEG股票新闻,以帮助您做出投资决策。